This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.
Dr. Sebastian Jungermann

Dr. Sebastian Jungermann

Complex Commercial Litigation Department

T: +49 69 25494 300
F: +49 69 25494 553

icon 下载联系方式



Philipps-Universität Marburg, Dr. iur., 2002

Zweites Juristisches Staatsexamen, Hessen, 1999

Landgericht Marburg, Oberlandesgericht Frankfurt am Main und Hessen, 1997-1999

Erstes Juristisches Staatsexamen, Hessen, 1997

Philipps-Universität Marburg, 1992-1997


  • German Attorney since 2000, authorized to represent before all German Courts (except for the Federal Court of Justice in civil matters) and before the courts of the European Union.


  • German Bar Association

  • German-American Lawyers' Association (DAJV)

  • German Association of Law and Informatics (DGRI)

  • German Association for the Protection of Intellectual Property and Copyrights (GRUR)

  • Studienvereinigung Kartellrecht (Antitrust Lawyers Association for Germany, Austria and Switzerland)

  • Antitrust-Forum Frankfurt (Kartellrechtsforum Frankfurt am Main)

  • American Bar Association (ABA), Section of Antitrust Law


  • German
  • English
  • Deutsch
  • Englisch

Dr. Sebastian Jungermann is a partner in Kaye Scholer’s Frankfurt office. Sebastian advises clients regarding German and European competition and antitrust laws, including German, EU and multi-jurisdictional merger control proceedings, cartel proceedings, abuse-of-dominance proceedings, litigation, compliance programs, as well as internal audits and contractual advice. Sebastian represents his clients before courts, the German Federal Cartel Office, the European Commission as well as the US Department of Justice. Sebastian further advises in the fields of corporate law, IP, data protection, outsourcing and other technology-related areas. In addition, Sebastian is involved in international litigation, including pre-trial discovery proceedings in support of US litigation.

Sebastian joined Kaye Scholer in 2002. In 2004, he worked at Kaye Scholer's New York office in their antitrust and corporate groups. Prior to joining Kaye Scholer, Sebastian worked at Linklaters in Frankfurt. In 2006, Sebastian was promoted to Counsel, in 2009 to Partner.

Sebastian is a co-author of Frankfurter Kommentar Kartellrecht, a leading commentary on German and European antitrust law and he regularly publishes articles in the fields of antitrust, compliance, corporate, and other related topics. Sebastian wrote his legal thesis on the use of electronic signatures as evidence in legal proceedings. Sebastian also has frequent speaking engagements on the topics of antitrust, compliance, and pre-trial discovery.

International and German legal directories recommend Sebastian as a “leading lawyer” in his field. Recommended by Chambers Europe 2013,  Chambers Europe 2014, and Chambers Europe 2015 as a leading antitrust practitioner, Sebastian is praised by impressed clients as being "very polite and extremely savvy on merger control and antitrust law”, for his “responsiveness, industry knowledge and commercial awareness,” and “clients praise his language abilities, saying: "His ability to explain a very unfamiliar legal framework in English is excellent." Sebastian was also named an Competition and Antitrust Life Science Star in Germany in the 2014 edition of Life Sciences Europe by Legal Media Group. Also the German JUVE Handbook 2015/2016, Legal 500 Deutschland and Kanzleien in Deutschland (Law Firms in Germany) praise Sebastian as a leading antitrust practitioner in Germany.

Sebastian is Chairman of the Board of the Antitrust Forum Frankfurt (Kartellrechtsforum Frankfurt am Main), a member of the Antitrust Lawyers Association for Germany, Austria and Switzerland (Studienvereinigung Kartellrecht), the American Bar Association - Section of Antitrust Law, the German Lawyers Association (Deutscher Anwaltverein), the German-American Lawyers' Association (DAJV), the German Association of Law and Informatics (DGRI), and the German Association for the Protection of Intellectual Property and Copyrights (GRUR).

Representative Matters

  • Onex, in its sale of The Warranty Group, a leading global provider of warranty solutions and related programs, to private equity firm TPG for an enterprise value of approximately US$1.5 billion.
  • The shareholders of Hastings Insurance Group, one of Europe's fastest growing insurance businesses, in the sale of 50 percent of Hastings voting share capital to Goldman Sachs Merchant Banking Division. The transaction was financed through a mixture of equity and new debt financing, implied a net enterprise value of approximately US$1.1 billion.
  • VanDeMark Chemical, the largest, independent manufacturer of phosgene and phosgene derivatives in North America, in its acquisition of Framochem from ISOCHEM.
  • MacDonald, Dettwiler and Associatesin the acquisition of Space Systems/Loral Inc. for US$875 million, a Palo Alto, California-based subsidiary of Loral Space & Communications that builds satellites primarily for commercial clients.
  • Bank of America Corp. in its sale, along with Barclays, of the remaining 26.5% stake in Archstone to Lehman Brothers Holdings Inc. for US$1.58 billion.
  • Bank of America Corp. in its sale, along with Barclays, of half of the banks’ stake, or 26.5% of Archstone, to Lehman Brothers Holdings Inc. for US$1.325 billion.
  • American Securitiesin its acquisition of Unifrax, the leading global manufacturer of high-temperature insulating fiber products.
  • Onex and its affiliates in their investment of US$871 million in JELD-WEN, a leading manufacturer of residential and light commercial interior and exterior doors, windows and related products.
  • Safran in its US$1.09 billion acquisition of L-1 Identity Solutions, Inc., which provides technology, products, systems and solutions, and services that protect and secure personal identities and assets.
  • Essie Cosmeticsin its acquisition by L'Oréal.
  • Sandoz, a subsidiary of Novartis, in its US$1.525 billion acquisition of specialty dermatology generics company Fougera Pharmaceuticals from a consortium of private equity funds led by Nordic Capital, DLJ Merchant Banking (a Credit Suisse affiliate) and Avista Capital Partners.
  • Jarden Corporationin its acquisition of Mapa Spontex Baby Care and Home Care Businesses from French conglomerate Total S.A for US$500 million.
  • Avail Medical Products, a privately-held market leader in disposable medical devices, and its shareholders in its sale by merger to Flextronics International.
  • Parsons Brinckerhoffin the sale of its infrastructure engineering and design firm to Balfour Beatty for US$626 million.
  • American Securitiesin its sale of Unifrax, a leading global manufacturer of high-temperature insulating fiber products.
  • Paris based SAFRAN-Groupin various high profile transactions, acquisitions and joint ventures.
  • Sodexo in various general matters including antitrust, compliance, litigation, human resources and corporate and finance.
  • Dimension Datain various transactions and general matters including antitrust, compliance, litigation, corporate and finance.
  • Honsel Family, also in connection with the sale of the HONSEL-Group to Carlyle, and the secondary buyout from Carlyle to Ripplewood.
  • German real estate investorsto recover title to property in Manhattan worth US$20 million including US pre-trial discovery.
  • Various Companies, Officers and Managersin antitrust investigations and proceedings before the German Cartel Authority, the European Commission and the US Department of Justice, including the investigations regarding Air Cargo, Auto Parts,­_Rolled Asphalt, Steel, Sanitary, Heating and Plumbing, Air Conditioning, E-Commerce and Information Technology, Pharmaceuticals, Chinaware, among others.
  • Various large companies from Germany and Switzerland in support of US pre-trial discovery and managing hundreds of custodians, terabytes of electronic data and large review teams located in Germany.
  • The shareholders of Zinsser Analytic, an established developer and provider of laboratory solutions as well as complementary consumables, and ILS Innovative Laborsysteme, a global supplier to leading laboratory equipment manufacturers and laboratories, in the sale to Gardner Denver, a KKR portfolio company.


Information pursuant to § 5 TMG and § 2 DL-InfoV